Iris Dotan

SOCIETY: AGA

BACKGROUND: Biological treatment in inflammatory bowel disease (IBD) patients is currently hampered by high non-response rates. To enhance personalized medicine and predict response to biological therapeutics such as vedolizumab, the working mechanism should be elucidated…

BACKGROUND: Early detection of inflammatory flares and corresponding treatment adjustment were shown to improve inflammatory bowel disease (IBD) patient care. Current episodic inflammatory biomarker testing allows limited monitoring and is associated with suboptimal compliance…

Background: Optimal strategies for treat-to-target in Crohn’s disease (CD) are still being sought. We aimed to examine the value of capsule endoscopy (CE) to guide proactive treatment optimization in patients with CD…

Although the cause of Crohn’s disease (CD) is unknown, recent studies have identified a number of biomarkers associated with the risk of developing CD in healthy at-risk individuals…

OBJECTIVE:The rapid emergence of IBD in newly industrialized regions supports the importance of environmental risk factors in disease etiology…

BACKGROUND: The Mediterranean diet (MED) is hypothesized to play a protective role in Crohn’s disease (CD) etiology, yet the underlying mechanisms remain unclear…